Market closed
Greenwich LifeSciences/$GLSI
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Greenwich LifeSciences
Greenwich LifeSciences Inc is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. Its Product Candidates include; GP2, a HER2/neu transmembrane peptide that elicits a targeted immune response against HER2/neu-expressing cancers, GM-CSF Immunoadjuvant has been shown to enhance monocyte and neutrophil cytotoxicity against melanoma tumor cells and to enhance activity-dependent cellular cytotoxicity of monocytes and neutrophils against targets coated with the anti-ganglioside antibodies, and Cancer immunotherapy seeks to stimulate an individual's immune system to selectively attack cancer cells to inhibit the spread of cancer.
Ticker
$GLSI
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
5
Website
GLSI Metrics
BasicAdvanced
$167M
-
-$0.81
3.32
-
Price and volume
Market cap
$167M
Beta
3.32
52-week high
$21.44
52-week low
$8.00
Average daily volume
38K
Financial strength
Current ratio
6.912
Quick ratio
6.912
Management effectiveness
Return on assets (TTM)
-89.85%
Return on equity (TTM)
-151.72%
Valuation
Price to book
33.53
Price to tangible book (TTM)
33.55
Price to free cash flow (TTM)
-21.73
Growth
Earnings per share change (TTM)
15.73%
3-year earnings per share growth (CAGR)
45.06%
What the Analysts think about GLSI
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Greenwich LifeSciences stock.
GLSI Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
GLSI News
AllArticlesVideos
Greenwich LifeSciences Announces Additions of Harvard and Johns Hopkins to Flamingo-01
GlobeNewsWire·12 hours ago
Greenwich LifeSciences Provides Update on Commercial Manufacturing
GlobeNewsWire·2 days ago
Glancy Prongay & Murray LLP Announces Investigation of Greenwich LifeSciences, Inc. (GLSI)
Business Wire·6 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Greenwich LifeSciences stock?
Greenwich LifeSciences (GLSI) has a market cap of $167M as of January 23, 2025.
What is the P/E ratio for Greenwich LifeSciences stock?
The price to earnings (P/E) ratio for Greenwich LifeSciences (GLSI) stock is 0 as of January 23, 2025.
Does Greenwich LifeSciences stock pay dividends?
No, Greenwich LifeSciences (GLSI) stock does not pay dividends to its shareholders as of January 23, 2025.
When is the next Greenwich LifeSciences dividend payment date?
Greenwich LifeSciences (GLSI) stock does not pay dividends to its shareholders.
What is the beta indicator for Greenwich LifeSciences?
Greenwich LifeSciences (GLSI) has a beta rating of 3.32. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.